MYCOMAX 150mg x 1 tabl
Mycomax is indicated in the following fungal infections (see section 5.1). Mycomax is indicated in adults for the treatment of: • Cryptococcal meningitis (see section 4.4). • Coccidioidomycosis (see section 4.4). • Invasive candidiasis • Mucosal candidiasis, including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. • Chronic oral atrophic candidiasis (inflammation of the mouth as a result of dentures), in case dental hygiene or topical treatment is insufficient • Vaginal candidiasis, acute or recurrent, when topical treatment is not appropriate. • Candidal balanitis, when topical treatment is not appropriate. • Dermatomycosis, including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and skin infection with candida, when systemic treatment is indicated. • Tinea unguinium (onychomycosis) when other agents are considered unsuitable. Mycomax is indicated in adults for the prevention of: • Recurrence of cryptococcal meningitis in patients at high risk of recurrence. • Recurrence of oropharyngeal or oesophageal candidiasis in patients infected with HIV or at increased risk of recurrence. • To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes per year) • Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients undergoing haematopoietic stem cell transplantation (see section 5.1)). Mycomax is indicated in term neonates, infants, toddlers, children and adolescents aged 0 to 17 years: Mycomax is used in the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and prophylaxis of candidiasis in immunocompromised patients. Mycomax can be used as maintenance therapy to prevent recurrence of cryptococcal meningitis in children at high risk of recurrence (see section 4.4). Treatment may be initiated before the results of microbiological and other laboratory tests are known; however, when the results are known, therapy should be adjusted appropriately. Official recommendations for the proper use of antifungals should be taken into account. Fluconazole 150 mg
